Number of the records: 1
Multiple myeloma, immunotherapy and minimal residual disease
Title Multiple myeloma, immunotherapy and minimal residual disease : minireview Author Kusenda Ján 1961- SAVEXONK ; SAVBIOMED - Ústav experimentálnej onkológie SAV RID ORCID Co-authors Kovaríková Anna 1963- SAVEXONK ; SAVBIOMED - Ústav experimentálnej onkológie SAV Source document Neoplasma. Vol. 63, no. 5 (2016), p. 651-658 Language eng - English Country SK - Slovak Republic Document kind rozpis článkov z periodík (rbx) Citations CHANG, S. K. - HOU, J. - CHEN, G. G. - YU, D. D. - WU, H. Q. - XIE, Y. S. - HU, L. N. - GAO, L. - XIAO, W. Q. - KONG, Y. Y. - TAO, Y. - SHI, J. M. Carfilzomib combined with ex vivo-expanded patient autologous natural killer cells for myeloma immunotherapy. In NEOPLASMA. ISSN 0028-2685, 2018, vol. 65, no. 5, pp. 720-729. WANG, Gang - NING, Fang-Ying - WANG, Jia-Heng - YAN, Hai-Meng - KONG, Hong-Wei - ZHANG, Yu-Ting - SHEN, Qiang. Expression of interleukin-32 in bone marrow of patients with myeloma and its prognostic significance. In WORLD JOURNAL OF CLINICAL CASES. ISSN 2307-8960, 2019, vol. 7, no. 24, pp. 4234-4244. Category ADDA - Scientific papers in domestic journals registered in Current Contents Connect with IF (impacted) Category of document (from 2022) V3 - Vedecký výstup publikačnej činnosti z časopisu Type of document článok Year 2016 Registered in WOS Registered in SCOPUS Registered in CCC DOI 10.4149/neo_2016_501 
article
File name Access Size Downloaded Type License Multiple myeloma, immunotherapy and minimal residual disease.pdf available 163.6 KB 1 Publisher's version rok CC IF IF Q (best) JCR Av Jour IF Perc SJR SJR Q (best) CiteScore A rok vydania rok metriky IF IF Q (best) SJR SJR Q (best) 2016 2015 1.961 Q3 0.738 Q3
Number of the records: 1